Companies
Nkarta
NKX101 (NKG2D CAR-NK) — phase I in acute myeloid leukaemia.
- Country
- United States
FDA IND
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $250.9 million in cash, cash equivalents, and investments as of December 31, 2023; over $381 million in cash as of December 31, 2024 | endpoints.news · ir.nkartatx.com · biopharmadive.com |
| Production site | Two cGMP facilities in South San Francisco, California | ir.nkartatx.com · sec.gov |
| Regulatory approval | Orphan Drug Designation for NKX101 for the treatment of acute myeloid leukemia (AML) granted by the FDA in December 2021 | sec.gov |
| Headcount | 108 employees as of March 31, 2026 | stockanalysis.com |
| Revenue | $0.000B as of 2026 | macrotrends.net |
Independent sources: biopharmadive.com · endpoints.news · macrotrends.net · sec.gov · stockanalysis.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| NK-cell & CAR-NK therapy | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.